Navigation Links
Enterovirus ASR

ProductsEnterovirus ASR
Company Cepheid
Item Enterovirus ASR
Features 
Description The Enterovirus ASR contains primers, a FAM-labeled probe and an Alexa 532-labeled probe that are designed to detect a 115 bp region of the 5' UTR. This ASR requires an instrument that can detect FAM, Alexa 532 and Texas Red reporter dyes like the Cepheid SmartCycler System.

The Cepheid Analyte Specific Reagent* (ASR) program is comprised of a series of easy-to-use primer and probe sets in a convenient lyophilized bead format. Every ASR product is manufactured under cGMP for maximum product consistency and quality. Cepheid ASRs are also delivered with an internal control** to ensure optimum reliability by confirming that negatives are truly negative not inhibited. Each ASR product is designed for rapid results on real-time PCR instruments like the Cepheid SmartCycler System.

* Analytical and performance characteristics are not established. ASRs can only be sold to clinical laboratories regulated under the CLIA of 1988, as qualified to perform high complexity testing under 42 CFR part 493 or under VHA directive 1106.
** See specific ASR product datasheet for internal control information.

Info Cepheid
Customer Service: (408) 541-4191
Web site: http://www.cepheid.com/

Related medicine products :

1. Enterovirus Culture
2. Enterovirus Detection by RT-PCR
3. Enterovirus Panel II
4. Enterovirus Typing
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 1WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 2WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 3Red Cross Offers the Trick to Safety this Halloween 60220 1Red Cross Offers the Trick to Safety this Halloween 60220 2Connectyx Announces the MedFlash Personal Health Manager 60218 1Connectyx Announces the MedFlash Personal Health Manager 60218 2Connectyx Announces the MedFlash Personal Health Manager 60218 3